Among patients with moderate to severe psoriasis, treatment options that are most compatible with their personal and professional life appear to be most important, and treatment location appears matter more than probability and magnitude of treatment outcome, according to a report in the November issue of Archives of Dermatology, one of the JAMA/Archives journals. As background information, the authors wrote: "As a chronic debilitating inflammatory disease of the skin and joints, psoriasis can cause considerable physical impairment. The well-being of patients is influenced not only by the disease but also by its management.Many patients, especially those with severe psoriasis, are dissatisfied with the management of their disease and frustrated by the perceived ineffectiveness of treatments.
Collaborative research from Perelman School of Medicine at the University of Pennsylvania has shown that psoriasis patients have an increased risk of heart attack, stroke and cardiovascular death, especially if the psoriasis is moderate to severe. Now, Penn researchers have discovered the potential underlying mechanism by which the inflammatory skin disease impacts cardiovascular health. In two new studies presented at the 2011 American Heart Association Scientific Sessions, Penn researchers show that the systemic inflammatory impact of psoriasis may alter both the makeup of cholesterol particles and numbers, as well as impair the function of high density lipoprotein (HDL), the "good" cholesterol. "Anecdotally, many researchers have observed that HDL levels may be lower in states of inflammation, such as rheumatoid arthritis, psoriasis and even obesity, " said lead study author Nehal Mehta, MD, MSCE, director of Inflammatory Risk in Preventive Cardiology at Penn.
According to a study published in the November issue of Archives for Dermatology, one of the JAMA/Archives journals and written by scientists from the Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, treatment options and locations for individuals suffering from moderate to severe psoriasis that are compatible with the patients' personal and professional lifestyle are more important than the probability and magnitude of treatment outcome. In their introduction to the article, the authors explained as background information: "As a chronic debilitating inflammatory disease of the skin and joints, psoriasis can cause considerable physical impairment. The well-being of patients is influenced not only by the disease by also by its management. Many patients, especially those with severe psoriasis, are dissatisfied with the management of their disease and frustrated by the perceived ineffectiveness of treatments.
'Good bugs' look promising as anti-inflammatory agent for patients with ulcerative colitis, psoriasis, chronic fatigue syndrome In four different studies presented at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC, researchers explored the effectiveness of probiotics for antibiotic-associated diarrhea; as an anti-inflammatory agent for patients with ulcerative colitis, psoriasis and chronic fatigue syndrome; and for people with abdominal discomfort and bloating who have not been diagnosed with a functional bowel disorder, such as irritable bowel syndrome (IBS). These four studies will be featured during an ACG press briefing on Tuesday, November 1, 2011 entitled: "Good, Bad and Ugly Bugs: Mother Nature as a Treatment for Better Health in the GI Tract, " which will highlight new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics and fecal microbiota transplantation in treating various GI conditions.
At the annual European Academy of Dermatology and Venereology (EADV) Congress in Lisbon, Portugal, Novartis announced positive results from its three Phase II trials of AIN457 (secukinumab), a drug designed for the treatment of psoriasis. The results revealed quick and significant improvements of symptoms in patients with moderate-to-severe plaque psoriasis. About 2% of people worldwide suffer from plaque psoriasis, with 30% of patients being affected moderately to severely by the disease, which is a common hereditary and immune-mediated systemic disorder that is characterized by skin lesions (plaques). The skin lesions linked to plaque psoriasis are associated with significant symptoms, including itching, scaling and pain, which can have a severe impact on those who suffer from chronic plaque psoriasis, as it ultimately influences a patient's emotional, social, physical and occupational functioning.